2021 mid-year CDMO review

In this special ‘bite-sized’ Molecule to Market episode, you’ll go inside the outsourcing space with returning guest Jim Miller, Independent consultant and advisor to the pharma and biotech manufacturing industry. Your host, Raman Sehgal, discusses what’s happened and what’s to come in the CDMO space as we near the half way mark of 2021. Inspired by his recent DCAT Value Chain Insights article, Jim covers:

• Vaccine manufacturing, capacity constraints and the increasing scale and role of the CDMO in the supply chain.
• 32+ recent M&A deals as well as the future landscape for more (and bigger) ventures.
• Very encouraging trends for CDMOs in terms of funding in the sector, likely preparation for future pandemics and the backlog in clinical trials.

Jim Miller is a renowned expert in the space and a regular speaker at all the major trade conferences including CPhI WW. He made his name in the sector after founding and growing PharmSource with his wife Judy, an online database on bio/pharmaceutical intelligence, before selling the business to Global Data. Today, he’s a industry consultant and regularly writes for leading industry publications such as DCAT and Pharmaceutical Technology.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life sciences outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.